CD79A and Respiratory tract infection: Traditional intramuscular administration does not provide a first line of protection against mucosal infection, especially in response to respiratory tract infections such as influenza or severe acute respiratory syndrome 2 (SARS‐CoV‐2), given the deficiencies in secretory IgA and IgG [46].